Jag Capital Management LLC Sells 1,223 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Jag Capital Management LLC cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Rating) by 5.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,064 shares of the company’s stock after selling 1,223 shares during the period. Jag Capital Management LLC’s holdings in IDEXX Laboratories were worth $13,870,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of IDXX. Garde Capital Inc. raised its stake in shares of IDEXX Laboratories by 2.7% during the third quarter. Garde Capital Inc. now owns 616 shares of the company’s stock valued at $383,000 after acquiring an additional 16 shares during the last quarter. Heartland Bank & Trust Co raised its stake in shares of IDEXX Laboratories by 2.2% during the fourth quarter. Heartland Bank & Trust Co now owns 938 shares of the company’s stock valued at $618,000 after acquiring an additional 20 shares during the last quarter. First National Bank of Hutchinson raised its stake in shares of IDEXX Laboratories by 1.8% during the fourth quarter. First National Bank of Hutchinson now owns 1,121 shares of the company’s stock valued at $738,000 after acquiring an additional 20 shares during the last quarter. SignalPoint Asset Management LLC raised its stake in shares of IDEXX Laboratories by 1.6% during the fourth quarter. SignalPoint Asset Management LLC now owns 1,420 shares of the company’s stock valued at $935,000 after acquiring an additional 22 shares during the last quarter. Finally, Mission Wealth Management LP raised its stake in shares of IDEXX Laboratories by 1.7% during the fourth quarter. Mission Wealth Management LP now owns 1,463 shares of the company’s stock valued at $963,000 after acquiring an additional 24 shares during the last quarter. 84.92% of the stock is owned by institutional investors and hedge funds.

IDXX has been the subject of several recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a research note on Wednesday, February 2nd. Atlantic Securities began coverage on shares of IDEXX Laboratories in a research note on Tuesday, February 8th. They issued an “overweight” rating and a $650.00 price target for the company. Bank of America downgraded shares of IDEXX Laboratories from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $550.00 to $470.00 in a research note on Thursday, May 5th. The Goldman Sachs Group decreased their price target on shares of IDEXX Laboratories from $615.00 to $530.00 and set a “neutral” rating for the company in a research note on Thursday, May 19th. Finally, StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, May 6th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Buy” and an average target price of $650.33.

IDEXX Laboratories stock traded up $17.06 during midday trading on Thursday, reaching $384.92. 841,962 shares of the company traded hands, compared to its average volume of 615,205. The firm has a market capitalization of $32.34 billion, a price-to-earnings ratio of 45.13, a price-to-earnings-growth ratio of 2.32 and a beta of 1.10. The business has a 50 day moving average of $460.33 and a two-hundred day moving average of $528.18. IDEXX Laboratories, Inc. has a 12 month low of $330.66 and a 12 month high of $706.95. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.12 and a quick ratio of 0.81.

IDEXX Laboratories (NASDAQ:IDXXGet Rating) last released its quarterly earnings results on Wednesday, May 4th. The company reported $2.27 earnings per share for the quarter, topping the consensus estimate of $2.25 by $0.02. IDEXX Laboratories had a net margin of 22.43% and a return on equity of 103.70%. The business had revenue of $836.55 million for the quarter, compared to the consensus estimate of $836.47 million. During the same period last year, the firm earned $2.35 earnings per share. The company’s quarterly revenue was up 7.6% on a year-over-year basis. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 8.24 EPS for the current year.

IDEXX Laboratories Profile (Get Rating)

IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

Read More

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Rating).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.